

## THIRTEENTH BASE PROSPECTUS SUPPLEMENT

Morgan Stanley

*as issuer and guarantor  
(incorporated under the laws of the State of Delaware in the United States of America)*

### MORGAN STANLEY & CO. INTERNATIONAL PLC

*as issuer  
(incorporated with limited liability in England and Wales)*

### MORGAN STANLEY B.V.

*as issuer  
(incorporated with limited liability in The Netherlands)*

### MORGAN STANLEY FINANCE LLC

*as issuer  
(formed under the laws of the State of Delaware in the United States of America)*

## REGULATION S PROGRAM FOR THE ISSUANCE OF NOTES AND CERTIFICATES, SERIES A AND SERIES B, AND WARRANTS

Morgan Stanley (“**Morgan Stanley**”), Morgan Stanley & Co. International plc (“**MSI plc**”), Morgan Stanley B.V. (“**MSBV**”) and Morgan Stanley Finance LLC (“**MSFL**”, together with Morgan Stanley, MSI plc and MSBV, the “**Issuers**”) and Morgan Stanley, in its capacity as guarantor (in such capacity, the “**Guarantor**”) have prepared this thirteenth base prospectus supplement (the “**Thirteenth Base Prospectus Supplement**”) to supplement and be read in conjunction with the base prospectus dated 15 July 2022 of Morgan Stanley, MSI plc, MSBV and MSFL (each in its capacity as Issuer) and Morgan Stanley (in its capacity as Guarantor) (as supplemented by the first supplement to the Base Prospectus dated 24 August 2022, the second supplement to the Base Prospectus dated 14 September 2022, the third supplement to the Base Prospectus dated 16 September 2022, the fourth supplement to the Base Prospectus dated 20 September 2022, the fifth supplement to the Base Prospectus dated 5 October 2022, the sixth supplement to the Base Prospectus dated 19 October 2022, the seventh supplement to the Base Prospectus dated 3 November 2022, the eighth supplement to the Base Prospectus dated 17 November 2022, the ninth supplement to the Base Prospectus dated 9 December 2022, the tenth supplement to the Base Prospectus dated 10 January 2023, the eleventh supplement to the Base Prospectus dated 23 January 2023 and the twelfth supplement to the Base Prospectus dated 16 March 2023, the “**Base Prospectus**”) relating to the Regulation S Program for the Issuance of Notes and Certificates, Series A and Series B, and Warrants.

This Thirteenth Base Prospectus Supplement has been approved by the Luxembourg *Commission de Surveillance du Secteur Financier* (the “**CSSF**”), as competent authority under Regulation (EU) 2017/1129 (the “**Prospectus Regulation**”) and constitutes a supplement for the purposes of Article 23(1) of the Prospectus Regulation.

The CSSF only approves this Thirteenth Base Prospectus Supplement as meeting the standard of completeness, comprehensibility and consistency imposed by the Prospectus Regulation and the CSSF gives no undertaking as to the economic and financial soundness of any transaction or the quality or solvency of the Issuers. Such approval should not be considered as an endorsement of the Issuers or the quality of the Notes that are the subject of this Thirteenth Base Prospectus Supplement.

This Thirteenth Base Prospectus Supplement has also been approved by the Luxembourg Stock Exchange pursuant to the rules and regulations of the Luxembourg Stock Exchange with respect to Exempt Notes for the purpose of providing information with regard to Program Securities for the purpose of listing Program Securities

on the Official List and to trading on the Euro MTF market of the Luxembourg Stock Exchange. The Euro MTF market is not a regulated market for the purposes of MiFID II. **The CSSF has neither approved nor reviewed information contained in this Thirteenth Base Prospectus Supplement in connection with the issue of any Exempt Notes.**

The Prospectus Regulation applies where the Notes are admitted to trading on a regulated market for the purpose of MiFID II and/or an offer of Notes is made to the public (within the meaning provided for the purposes of the Prospectus Regulation) in one or more Member States of the European Economic Area.

Unless otherwise defined in this Thirteenth Base Prospectus Supplement, terms defined in the Base Prospectus shall have the same meaning when used in this Thirteenth Base Prospectus Supplement. To the extent that there is any inconsistency between any statement in this Thirteenth Base Prospectus Supplement and any other statement in, or incorporated by reference in, the Base Prospectus, the statements in this Thirteenth Base Prospectus Supplement will prevail.

The purpose of this Thirteenth Base Prospectus Supplement is to:

- (a) disclose the publication by Morgan Stanley of its Current Report on Form 8-K dated 19 April 2023 for the quarterly period ended 31 March 2023 (the “**Morgan Stanley April 2023 Form 8-K**”);
- (b) incorporate the Morgan Stanley April 2023 Form 8-K by reference into the Base Prospectus, as set out in “Part A” of this Thirteenth Base Prospectus Supplement;
- (c) incorporate the third supplement to the Registration Document of Morgan Stanley, Morgan Stanley & Co. International plc, Morgan Stanley B.V. and Morgan Stanley Finance LLC dated 26 April 2023 (the “**Third Supplement to the Registration Document**”) by reference into the Base Prospectus, as set out in “Part A” of this Thirteenth Base Prospectus Supplement;
- (d) incorporate the Morgan Stanley Proxy Statement dated 6 April 2023 (the “**Morgan Stanley April 2023 Proxy Statement**”) by reference into the Base Prospectus, as set out in “Part A” of this Thirteenth Base Prospectus Supplement; and
- (e) make certain consequential amendments to the “*General Information*” section in the Base Prospectus, as set out in “Part B” of this Thirteenth Base Prospectus Supplement.

In accordance with Article 23.2 of the Prospectus Regulation, investors who have agreed to purchase or subscribe for, or have applied to purchase or subscribe for, any Notes prior to the publication of this Thirteenth Base Prospectus Supplement and where Securities had not yet been delivered to the investors at the time when the significant new factor, material mistake or material inaccuracy arose or was noted, shall have the right, exercisable within two Business Days following the date of publication of this Thirteenth Base Prospectus Supplement, to withdraw their acceptances or applications by notice in writing to the relevant Issuer or Manager, as the case may be. The final date within which such right of withdrawal must be exercised is 2 May 2023.

Save as disclosed in this Thirteenth Base Prospectus Supplement, no significant new factor, material mistake or inaccuracy relating to information included in the Base Prospectus has arisen since the publication of the Base Prospectus.

The Responsible Person (as defined below) accepts responsibility for the information contained in the relevant document and confirms that, to the best of its knowledge, having taken all reasonable care to ensure that such is the case, the information contained in the relevant document is in accordance with the facts and does not omit anything likely to affect the import of such information.

“**Responsible Person**” means Morgan Stanley with regard to this Thirteenth Base Prospectus Supplement which comprises this Thirteenth Base Prospectus Supplement.

This Thirteenth Base Prospectus Supplement is available for viewing, and copies may be obtained from the offices of the Responsible Person and is available on Morgan Stanley’s website at <https://sp.morganstanley.com/EU/Documents> and on the website of the Luxembourg Stock Exchange at

[www.luxse.com](http://www.luxse.com).

The Morgan Stanley April 2023 Form 8-K is available on Morgan Stanley's website at <https://sp.morganstanley.com/EU/Download/GeneralDocument?documentID=76d4521d-87cd-48c2-b9f9-e64f72e1f4ed> and on the website of the Luxembourg Stock Exchange at [www.luxse.com](http://www.luxse.com).

The Third Supplement to the Registration Document is available on Morgan Stanley's website at <https://sp.morganstanley.com/EU/Download/GeneralDocument?documentID=a59c95ae-3f7e-4f23-a201-671e75201045>.

The Morgan Stanley April 2023 Proxy Statement is available on Morgan Stanley's website at [https://www.morganstanley.com/content/dam/msdotcom/en/about-us-2022ams/2023\\_Proxy\\_Statement.pdf](https://www.morganstanley.com/content/dam/msdotcom/en/about-us-2022ams/2023_Proxy_Statement.pdf).

27 April 2023

**MORGAN STANLEY**

**MORGAN STANLEY & CO. INTERNATIONAL PLC**

**MORGAN STANLEY B.V.**

**MORGAN STANLEY FINANCE LLC**

## CONTENTS

	<b>Page</b>
<b>PART A - INCORPORATION BY REFERENCE</b>	<b>5</b>
<b>PART B – AMENDMENTS TO THE “GENERAL INFORMATION” SECTION</b>	<b>6</b>

## PART A – INCORPORATION BY REFERENCE

This Thirteenth Base Prospectus Supplement incorporates by reference the Morgan Stanley April 2023 Form 8-K, the Third Registration Document Supplement and the Morgan Stanley April 2023 Proxy Statement, and supplements the section entitled “*Incorporation by Reference*” contained on pages 87 to 105 of the Base Prospectus.

The following document and/or information shall be deemed to be incorporated by reference in, and form a part of, the Base Prospectus:

Document filed	Information incorporated by reference	Page(s) <sup>1</sup>
Morgan Stanley April 2023 Form 8-K	(1) Results of Operations and Financial Condition	3
<a href="https://sp.morganstanley.com/EU/Download/GeneralDocument?documentID=76d4521d-87cd-48c2-b9f9-e64f72e1f4ed">https://sp.morganstanley.com/EU/Download/GeneralDocument?documentID=76d4521d-87cd-48c2-b9f9-e64f72e1f4ed</a>	(2) Financial Statements and Exhibits	3
	(3) Press release of Morgan Stanley, dated 19 April 2023, containing financial information for the quarter ended 31 March 2023	4-12
	(4) Financial Data Supplement of Morgan Stanley for the quarter ended 31 March 2023	13-31
	(1) Part A – Incorporation by Reference	4
Third Supplement to the Registration Document  <a href="https://sp.morganstanley.com/EU/Download/GeneralDocument?documentID=a59c95ae-3f7e-4f23-a201-671e75201045">https://sp.morganstanley.com/EU/Download/GeneralDocument?documentID=a59c95ae-3f7e-4f23-a201-671e75201045</a>		
Morgan Stanley April 2023 Proxy Statement  <a href="https://www.morganstanley.com/content/dam/msdotcom/en/about-us-2022ams/2023_Proxy_Statement.pdf">https://www.morganstanley.com/content/dam/msdotcom/en/about-us-2022ams/2023_Proxy_Statement.pdf</a>	(1) Overview of Voting Items	5-12
	(2) Corporate Governance Matters	13-46
	(3) Audit Matters	47-51
	(4) Compensation Matters	52-91
	(5) Ownership of Our Stock	92-94
	(6) Other Company Proposal	95
	(7) Shareholder Proposals	96-103
	(8) Information about the Annual Meeting	104-108

Any non-incorporated parts of a document referred to herein are either deemed not relevant for an investor or are otherwise covered elsewhere in the Base Prospectus.

<sup>1</sup> As portions of the Morgan Stanley April 2023 Form 8-K are unpaginated, the references to page numbers in relation to the Morgan Stanley April 2023 Form 8-K are in reference to the PDF page numbering.

**PART B - AMENDMENTS TO THE “GENERAL INFORMATION” SECTION**

1. Sub-paragraph (h) set out on page 1022 of the Base Prospectus shall be deemed to be deleted in its entirety and the following substituted therefor:

*“Morgan Stanley’s Annual Report on Form 10-K for the year ended 31 December 2022, Morgan Stanley’s Current Reports on Form 8-K dated 17 January 2023 and 19 April 2023, and Morgan Stanley’s Proxy Statement dated 6 April 2023;”*